Royal Bank Of Canada Forecasts Strong Price Appreciation for McKesson (NYSE:MCK) Stock

McKesson (NYSE:MCK) had its price objective boosted by stock analysts at Royal Bank Of Canada from $845.00 to $965.00 in a research report issued on Thursday, Benzinga reports. The firm presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s price target suggests a potential downside of 10.98% from the company’s previous close.

Several other equities analysts have also issued reports on the company. Evercore reaffirmed an “outperform” rating and set a $950.00 price target (down from $1,000.00) on shares of McKesson in a research note on Thursday, August 6th. Bank of America lifted their price objective on McKesson from $950.00 to $1,050.00 in a research report on Thursday, August 6th. Leerink Partners upped their target price on shares of McKesson from $1,030.00 to $1,070.00 and gave the company an “outperform” rating in a research report on Wednesday, October 7th. Wall Street Zen raised shares of McKesson from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Finally, Robert W. Baird set a $1,015.00 price target on shares of McKesson in a research report on Thursday, August 6th. Fifteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and an average price target of $1,004.18.

McKesson Price Performance

Shares of MCK stock traded up $14.59 during trading hours on Thursday, reaching $1,084.03. 804,091 shares of the company were exchanged, compared to its average volume of 917,716. The company has a market cap of $126.39 billion, a price-to-earnings ratio of 28.97, a P/E/G ratio of 1.99 and a beta of 0.27. The stock’s fifty day moving average is $931.17 and its two-hundred day moving average is $865.74. McKesson has a fifty-two week low of $723.68 and a fifty-two week high of $1,121.50.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The firm had revenue of $110.96 billion during the quarter, compared to analysts’ expectations of $109.90 billion. During the same quarter in the previous year, the company posted $9.86 EPS. McKesson’s revenue was up 7.5% on a year-over-year basis. On average, research analysts anticipate that McKesson will post 44.71 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Francisco Fraga sold 800 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $995.80, for a total value of $796,640.00. Following the sale, the executive vice president directly owned 5,423 shares in the company, valued at $5,400,223.40. This trade represents a 12.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bradley E. Lerman sold 301 shares of McKesson stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total transaction of $268,591.33. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 1,212 shares of company stock worth $1,164,182. Insiders own 0.06% of the company’s stock.

Institutional Investors Weigh In On McKesson

Several large investors have recently bought and sold shares of MCK. DSG Capital Advisors LLC grew its stake in McKesson by 20.0% in the third quarter. DSG Capital Advisors LLC now owns 4,134 shares of the company’s stock valued at $3,530,000 after acquiring an additional 690 shares during the period. Northbridge Financial Group LLC grew its position in shares of McKesson by 2.1% in the 3rd quarter. Northbridge Financial Group LLC now owns 766 shares of the company’s stock valued at $706,000 after purchasing an additional 16 shares during the period. AMG National Trust Bank increased its stake in McKesson by 2.0% during the 3rd quarter. AMG National Trust Bank now owns 3,596 shares of the company’s stock worth $3,071,000 after purchasing an additional 69 shares in the last quarter. Keybank National Association OH increased its stake in McKesson by 4.5% during the 3rd quarter. Keybank National Association OH now owns 4,460 shares of the company’s stock worth $3,808,000 after purchasing an additional 192 shares in the last quarter. Finally, Cornerstone Wealth Management LLC acquired a new stake in McKesson during the 3rd quarter worth approximately $256,000. Institutional investors own 85.07% of the company’s stock.

Key McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson reported adjusted EPS of $11.68, ahead of analysts’ roughly $10.70–$10.72 estimates, while revenue of $110.96 billion topped expectations of $109.9 billion and grew about 7.5% year over year. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: The company raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40. Management cited specialty distribution, higher prescription volumes and GLP-1 momentum as growth drivers. McKesson Corp (MCK) Q2 2027 Earnings Call Highlights
• Positive Sentiment: TD Cowen and Evercore ISI each raised their price target to $1,200, from $1,006 and $1,000, respectively—signaling improved analyst expectations after the results. TD Cowen Adjusts Price Target Evercore ISI Adjusts Price Target
• Neutral Sentiment: McKesson closed its $2.25 billion Precision Medicine Group acquisition, expanding its position in precision medicine. The deal offers growth potential, with execution and integration still to come. McKesson Outlook and Precision Medicine Deal
• Negative Sentiment: Some investors appeared cautious despite the earnings beat, with reports describing an after-hours stock dip. Earlier coverage also flagged branded-drug pricing pressure as a potential headwind. Q2 Earnings and Outlook

About McKesson

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and medical products to pharmacies, hospitals, health systems, physicians and other healthcare providers. The company also provides technology, data and business solutions designed to support prescription management, pharmacy operations and patient care.

McKesson’s principal activities include pharmaceutical distribution, medical-surgical supply distribution, specialty pharmaceutical services and oncology care support.